Akero Therapeutics Inc.
Akero Therapeutics, a Novo Nordisk subsidiary, develops efruxifermin (EFX), an FGF21 analog for metabolic disease, including MASH. Licensed to Amgen for manufacturing and commercialization, EFX targets lipid, carbohydrate, and protein metabolism in patients.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 74
- HQ: South San Francisco
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.